Search PubMed⌕ Search

Biomedical subjects

M Weber

Publications and source records attributed to M Weber.

At least 775 records · Page 43Linked to original sources
PubMed1978

A new pattern of non-organ- and non-species-specific anti-organelle antibody detected by immunofluorescence: the mitochondrial antibody number 5.

About 0.1% of the sera in human pathology produce a peculiar, cytoplasmic, non-organ- and non-species-specific fluorescence. This may easily be differentiated from the already described anti-organelle antibodies and, more particularly, from the mitochondrial antibodies of primary biliary cirrhosis. Should rat tissues be used in the immunofluorescence test, fluorescence predominates over the first two portions of the renal proximal tubules (P1 and P2) and the mucous neck cells of the stomach. This pattern may be atrributed to mitochondria, and in particular to their inner membranes by fluorescent staining of the ellipsoid region of the rods and cones of the eyes, and by absorption with purified organelles. To distinguish this antibody from the already described mitochondrial antibodies, this one will be called mitochondrial antibody number 5 (M5). The seven carriers of this antibody suffer from systemic lupus erythematosus or autoimmune haemolytic anaemia. In these cases no diseases of the liver were observed, contrary to other classical mitochondrial antibodies.

Adult↗
PubMed1977

[Pyoderma gangrenosum: Clofazimine therapy].

Two patients with pyoderma gangrenosum have responded remarkably well to treatment with Clofazimine (Lamprène). The first patient, a 68-year old women suffered from pyoderma gangrenosum of the buttock and left leg and on the incision scar for cancer of the breast. Laboratory findings showed monoclonal dysglobulinemia (alpha 2-kappa 2). A daily dose of 300 mg of Clofazimine resulted in complete healing with ten days. The second patient was a 24-year old women suffering from ulcerative colitis and a rapidly progressing pyoderma gangrenosum of the left leg. The lesions was completely healed after two weeks of Clofazimine therapy. The dosage was 200 mg daily and was increased to 400 mg daily. Our cases showed decreased cellular immunity and their phagocytic activity was variable.

Adult↗
PubMed1977

[Epilepsy, anticonvulsants and pregnancy].

A statistical study, using a computer, of 343 epileptic women with 775 pregnancies led to the following conclusions: 1. The influence of pregnancy on epilepsy is very variable: null once out of 2 times, pregnancy is more often favourable than unfavourable in the remaining 50% of the cases. 2. The influence of epilepsy on pregnancy seems to be null with regard to the course of pregnancy, its termination and the post-delivery period. The perinatal mortality rate is, however, higher. 3. Concerning the very present question of the teratogenic risk due to anticonvulsants, it appears that an epileptic woman has a slightly higher risk to bear a child with a congenital defect than does a non-epileptic mother; 4.04% of malformations in treated epileptic women, 2.32% in non-treated; 2.2% and 1.8% in two control groups.

Abnormalities, Drug-Induced↗